Spasticity

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

Retrieved on: 
Thursday, October 26, 2023
Cosmetics, Medical Supplies, Retail, Health, Other Health, Pharmaceutical, Biotechnology, Patient, Hubli railway division, FDA, Dermatology, Physician, Invention, Spasticity, Skin, Research, Speech, Torticollis, Dysphagia, AI, Neurotoxin, Muscular system, Death, Fine chemical, Vaccine, Dietary supplement, Pharmaceutical industry

TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.

Key Points: 
  • TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.
  • The entrants were then evaluated against a number of key factors, including originality, efficacy, ambition, and impact.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Pentec Health's Specialty Care Nurse Fellowship Granted Accreditation With Distinction by the American Nurses Credentialing Center

Retrieved on: 
Thursday, October 19, 2023
Insurance, Education, Distinction, Nursing, American Nurses Credentialing Center, Spasticity, Health, Accreditation, Mentorship, Coordinated Specialty Care, Trust, COVID, Patient satisfaction, ANCC, Safety, Pain management, Pharmacist, Patient, GLEN, Hospital

GLEN MILLS, Pa., Oct. 19, 2023 /PRNewswire-PRWeb/ -- Pentec Health, Inc.'s (Pentec) Specialty Care Nurse Fellowship has been granted Accreditation with Distinction, the highest recognition bestowed by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation in Practice Transition Programs.

Key Points: 
  • Pentec Health, Inc.'s (Pentec) Specialty Care Nurse Fellowship has been granted Accreditation with Distinction, the highest recognition bestowed by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation in Practice Transition Programs.
  • GLEN MILLS, Pa., Oct. 19, 2023 /PRNewswire-PRWeb/ -- Pentec Health, Inc.'s (Pentec) Specialty Care Nurse Fellowship has been granted Accreditation with Distinction, the highest recognition bestowed by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation in Practice Transition Programs.
  • A recent survey underscores just how much patients value that level of care, with 75% of those receiving Pentec Specialty Care services rating their care as a perfect 10.
  • A Complex Care provider, Pentec provides clinical nutrition – including medical foods and renal nutrition – in addition to specialty infusion care.

Merz Therapeutics Hosts Over 300 International Healthcare Professionals at its First Global “Merz Expert Connect Summit 2023”

Retrieved on: 
Friday, October 6, 2023
Medical Devices, Health, Hospitals, Health Technology, Pharmaceutical, Biotechnology, Stroke, Research, Medicine, AB toxin, Summit, Neurology, Travel, Patient, Therapy, Education, International Material Data System, Merz, DSM-IV codes, Cerebral palsy, Torticollis, Neurotoxin, Spasticity, Hypersalivation, Physician, Nursing

Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today.

Key Points: 
  • Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today.
  • More than 300 international experts in rehabilitation medicine and neurology will attend the event in Berlin from 6–7 October.
  • The “Merz Expert Connect Summit” is the largest global stand-alone event of its scale in the company’s history.
  • The program of the “Merz Expert Connect Summit” features more than 27 lectures by international thought leaders on a variety of relevant topics.

Texas Original Opens North Austin Medical Cannabis Pickup Location, Expanding Access in Central Texas

Retrieved on: 
Wednesday, September 27, 2023
Alternative Medicine, Other Consumer, Health, General Health, Cannabis, Women, Pharmaceutical, Men, Mental Health, Natural Resources, Consumer, Epilepsy, Seizure, Telehealth, Hurst, Travel, Diabetic neuropathy, Cancer, Prescription, Sweet Dreams, Cedar Park, Patient, Physician, Originality, Family, Spasticity, PTSD, Migraine, Amusement park, Health insurance, Central Texas

Texas Original , Texas’ leading medical cannabis provider, today announced its new prescription pickup location opened in North Austin.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced its new prescription pickup location opened in North Austin.
  • The North Austin location is Texas Original’s fourth in Central Texas, joining the company’s South Austin headquarters and dispensary and other locations in Waco and San Antonio.
  • “We are the leaders of medical cannabis cultivation and distribution in Texas, starting with our hometown of Austin.
  • Texans can obtain medical cannabis prescriptions through online clinics or local physicians registered with the Compassionate Use Registry of Texas.

ONWARD® Reports 2023 Half Year Results and Business Update

Retrieved on: 
Tuesday, September 19, 2023
Kepler, Lead, US Foods, IPG, Mayo Clinic, Nature, University, BCI, Marketing, Spinal cord, ARC, Neurology, American Academy, Neuroscience, Research, Quality, Movement, Government, EUR, BDD, Euronext, Spasticity, Assistant professor, Christopher and Dana Reeve Foundation, Paralysis, Johnson & Johnson, Clinical professor, Bdd, SCI, FDA, Global marketing, Pharmaceutical industry

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced its first 2023 half results and provided a Business Update.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced its first 2023 half results and provided a Business Update.
  • “We have also taken the difficult but correct decision to update the ARC-EX system circuit board assembly.
  • The Company announced four new Breakthrough Device Designations (BDD) from the US Food and Drug Administration (FDA) in the first half of 2023.
  • The Company ended the six-month period with a positive cash balance of EUR 43.8 million (31 December 2022: EUR 61.8 million).

Texas Original Continues Dallas-Fort Worth Expansion, Opens Plano Permanent Medical Cannabis Location

Retrieved on: 
Tuesday, August 29, 2023
Other Consumer, Mental Health, Women, Cannabis, Men, Alternative Medicine, General Health, Consumer, Health, Natural Resources, Epilepsy, Seizure, Uncertainty, Telehealth, Life, Convulsion, Diabetic neuropathy, Cancer, Prescription, Medicine, Sweet Dreams, Expanded access, Terpene, CUP, CBN, Suite, Cannabinol, Patient, Physician, Originality, THC, Dallas–Fort Worth metroplex, Spasticity, PTSD, Drug, Pharmaceutical industry, Hurst, DFW

Texas Original , Texas’ leading medical cannabis provider, announced today the opening of a permanent pickup location in Plano.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, announced today the opening of a permanent pickup location in Plano.
  • To celebrate the opening and to make medical cannabis more accessible to Texans, Texas Original has partnered with a telemedicine clinic to offer 50 free, one-year prescriptions to Plano permanent pickup location visitors on a first-come, first-served basis.
  • Prospective patients can visit the Plano location beginning Aug. 31 to book an appointment with the telemedicine clinic’s CUP-registered physicians to receive a prescription for medical cannabis.
  • Texas Original advances its commitment to expanding patient access to cannabis medicine amid lawmakers' failure to broaden medical cannabis regulation during the 2023 Texas regular legislative session.

Centura Study Finds NeuFit Direct Current Neuromuscular Electrical Stimulation to improve spasticity and functional outcomes in individuals with multiple sclerosis (MS)

Retrieved on: 
Thursday, August 24, 2023
Exercise, Anecdote, UTI, Spinal cord, Diabetic neuropathy, DSM-IV codes, Quality of life, Weakness, PT, Disability studies, Brain, Research, Facial muscles, Falls, NMES, Doctor of Philosophy, PNS, MS, EDSS, Clonus, Motion, Patient, Mechanoreceptor, Clutch (eggs), FDA, DPT, Spasticity, Atrophy, Peripheral nervous system, Dietary supplement, Medical device, Nursing

AUSTIN, Texas, Aug. 24, 2023 /PRNewswire/ -- A case series conducted by Dr. Courtney Ellerbusch, PT, DPT, of Centura Home Health (Colorado) on MS patients finds quantitative improvements in strength, spasticity, and range of motion over a series of 18 treatments with Neubie Direct Current neuromuscular electrical stimulation (NMES) therapy.

Key Points: 
  • These issues can contribute to muscle imbalances, postural problems and asymmetries, difficulty with activities of daily living, and falls.
  • "I [completed] this project for the individuals who face a daily reality in MS that has changed everything about their lives.
  • The Neubie Device uses direct current electrical stimulation to communicate with mechanoreceptors of the peripheral nervous system (PNS).
  • This action supports functional changes for a variety of FDA-cleared indications, including neuromuscular re-education and increasing range of motion.

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Retrieved on: 
Monday, August 14, 2023
FDA, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Neurotoxin, Therapy, Dysphagia, New England Institute of Religious Research, Muscular system, Speech, OLS, Head, Hubli railway division, Headache, Trial of the century, Pain, Spasmodic torticollis, Physician, Patient, The Retreat, Torticollis, ASPEN, Recurrence, Death, Spasticity, Acetylcholine, Pharmaceutical industry

Peter McAllister, M.D., ASPEN investigator and co-founder and medical director of the New England Institute for Neurology and Headache, commented: “As an ASPEN investigator, I am excited to see the approval of a new treatment option to address symptom reemergence prior to retreatment, a common issue for cervical dystonia patients. Currently, patients experience painful and life-limiting symptom recurrence as early as eight to 10 weeks in clinical practice but cannot be re-treated until 12 weeks. DAXXIFY® is the first long-acting neuromodulator that has the potential to address this significant unmet need -- demonstrating durable symptom relief between treatment cycles and providing the opportunity to extend treatment intervals.”

Key Points: 
  • In 2017, the U.S. FDA granted orphan drug designation to DAXXIFY® for the treatment of cervical dystonia in adults.
  • Further, we believe FDA approval represents a significant advancement in the treatment of cervical dystonia,” said Chief Executive Officer Mark J. Foley.
  • “DAXXIFY’s differentiated efficacy, duration and safety profile can help physicians deliver long-lasting symptom relief to patients suffering from cervical dystonia, while also helping payers address the total cost of care for this population.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

Merz Therapeutics’ XEOMIN® (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Neurotoxin, Injection, AB toxin, Health care, Stroke, Medication, Ankle, Patient, United Kingdom, Therapy, Spasticity, Merz, MHRA, Pharmaceutical industry

“The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve.

Key Points: 
  • “The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve.
  • This approval supports our strong commitment to bringing better outcomes to more patients,” says Stefan König, CEO Merz Therapeutics.
  • John Lambert, Country Manager of Merz Therapeutics UK & Ireland: “This new therapeutic indication supports an extension of the benefit XEOMIN® can bring in the treatment of spasticity.
  • The therapeutic indication is based on trial data from Japan, where XEOMIN® was also approved for treatment of the lower limb region in 2021.

PathMaker Neurosystems Receives $200,000 START Award from MassVentures

Retrieved on: 
Monday, June 5, 2023
Transfer, SBIR, Clinical trial, DSM-IV codes, NIH, Research, NINDS, Small business, Entrepreneurship, Service, ALS, Spasticity, Pharmaceutical industry

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, was selected as one of five companies in Massachusetts to receive a START Stage 2 award from MassVentures, which funds deep tech startups based in Massachusetts as they advance technology developed under SBIR/STTR grant funding.

Key Points: 
  • BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, was selected as one of five companies in Massachusetts to receive a START Stage 2 award from MassVentures, which funds deep tech startups based in Massachusetts as they advance technology developed under SBIR/STTR grant funding.
  • “We are grateful for the Stage 2 award from MassVentures as we work to bring MyoRegulator® to market,” said Nader Yaghoubi, M.D., Ph.D., Co-Founder and Chief Executive Officer of PathMaker.
  • The MassVentures START program helps deep tech startups convert their Small Business Innovation and Small Business Technology Transfer research (SBIR/STTR) into businesses and jobs in Massachusetts.
  • This $200,000 START Stage 2 award will enable late-stage development activities on MyoRegulator®, and follows a $100,000 START Stage 1 award funded in 2022.